Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
138 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Autism - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H2 2017, provides an overview of the Autism (Central Nervous System) pipeline landscape. Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.? Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 1, 18, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively. Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Autism - Overview Autism - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Autism - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Autism - Companies Involved in Therapeutics Development 4D Pharma PLC Addex Therapeutics Ltd Aequus Pharmaceuticals Inc Aevi Genomic Medicine Inc AgeneBio Inc Anima Biotech Ltd APeT Holding BV BioCrea GmbH BioHealthonomics Inc BrainStorm Cell Therapeutics Inc Confluence Pharmaceuticals LLC Coronis NeuroSciences Ltd Curemark LLC DRI Biosciences Corp F. Hoffmann-La Roche Ltd GW Pharmaceuticals Plc Heptares Therapeutics Ltd Immuron Ltd Intra-Cellular Therapies Inc Leading BioSciences Inc MedDay SA Omeros Corp OptiNose US Inc Ovensa Inc Q BioMed Inc Sumitomo Dainippon Pharma Co Ltd Autism - Drug Profiles acamprosate calcium - Drug Profile Product Description Mechanism Of Action R&D Progress ACT-01 - Drug Profile Product Description Mechanism Of Action R&D Progress ADX-71441 - Drug Profile Product Description Mechanism Of Action R&D Progress ADX-88178 - Drug Profile Product Description Mechanism Of Action R&D Progress Antibody to Inhibit Lipopolysaccharide for Autism - Drug Profile Product Description Mechanism Of Action R&D Progress aripiprazole - Drug Profile Product Description Mechanism Of Action R&D Progress ASD-002 - Drug Profile Product Description Mechanism Of Action R&D Progress Biologics for Autism - Drug Profile Product Description Mechanism Of Action R&D Progress CB-0306 - Drug Profile Product Description Mechanism Of Action R&D Progress CM-AT - Drug Profile Product Description Mechanism Of Action R&D Progress CP-102 - Drug Profile Product Description Mechanism Of Action R&D Progress Drug for Autism - Drug Profile Product Description Mechanism Of Action R&D Progress Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs for Autism - Drug Profile Product Description Mechanism Of Action R&D Progress fasoracetam - Drug Profile Product Description Mechanism Of Action R&D Progress GWP-42006 - Drug Profile Product Description Mechanism Of Action R&D Progress histamine dihydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress HTL-14242 - Drug Profile Product Description Mechanism Of Action R&D Progress IMM-124E - Drug Profile Product Description Mechanism Of Action R&D Progress L-179 - Drug Profile Product Description Mechanism Of Action R&D Progress lumateperone tosylate - Drug Profile Product Description Mechanism Of Action R&D Progress lurasidone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress MD-1103 - Drug Profile Product Description Mechanism Of Action R&D Progress niacinamide CR - Drug Profile Product Description Mechanism Of Action R&D Progress NurOwn - Drug Profile Product Description Mechanism Of Action R&D Progress oxytocin - Drug Profile Product Description Mechanism Of Action R&D Progress PAM-28 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Insulin Like Growth Factor 1 - Drug Profile Product Description Mechanism Of Action R&D Progress RG-7314 - Drug Profile Product Description Mechanism Of Action R&D Progress SERx-519 - Drug Profile Product Description Mechanism Of Action R&D Progress SF-999 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Target GPR63 for Autism - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Autism - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize CB1 and CB2 for Autism, Eczema and Insomnia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile Product Description Mechanism Of Action R&D Progress TTA-121 - Drug Profile Product Description Mechanism Of Action R&D Progress Autism - Dormant Projects Autism - Discontinued Products Autism - Product Development Milestones Featured News & Press Releases Apr 19, 2017: BrainStorm Announces Publication of NurOwn Autism Research Study Feb 23, 2017: Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism - The BlUm Study Sep 22, 2016: Blum Study - A Phase 3 Clinical Trial for Children with Autism Jul 20, 2016: Immuron to Cooperate with Leading Australian Universities on Autism Research Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism May 31, 2012: Study Reports New Treatment For Irritability In Autism Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism Oct 27, 2010: Curemark Adds Two Autism Trial Sites In California Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Autism, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Autism - Pipeline by 4D Pharma PLC, H2 2017 Autism - Pipeline by Addex Therapeutics Ltd, H2 2017 Autism - Pipeline by Aequus Pharmaceuticals Inc, H2 2017 Autism - Pipeline by Aevi Genomic Medicine Inc, H2 2017 Autism - Pipeline by AgeneBio Inc, H2 2017 Autism - Pipeline by Anima Biotech Ltd, H2 2017 Autism - Pipeline by APeT Holding BV, H2 2017 Autism - Pipeline by BioCrea GmbH, H2 2017 Autism - Pipeline by BioHealthonomics Inc, H2 2017 Autism - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2017 Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2017 Autism - Pipeline by Coronis NeuroSciences Ltd, H2 2017 Autism - Pipeline by Curemark LLC, H2 2017 Autism - Pipeline by DRI Biosciences Corp, H2 2017 Autism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Autism - Pipeline by GW Pharmaceuticals Plc, H2 2017 Autism - Pipeline by Heptares Therapeutics Ltd, H2 2017 Autism - Pipeline by Immuron Ltd, H2 2017 Autism - Pipeline by Intra-Cellular Therapies Inc, H2 2017 Autism - Pipeline by Leading BioSciences Inc, H2 2017 Autism - Pipeline by MedDay SA, H2 2017 Autism - Pipeline by Omeros Corp, H2 2017 Autism - Pipeline by OptiNose US Inc, H2 2017 Autism - Pipeline by Ovensa Inc, H2 2017 Autism - Pipeline by Q BioMed Inc, H2 2017 Autism - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 Autism - Dormant Projects, H2 2017 Autism - Dormant Projects, H2 2017 (Contd..1), H2 2017 Autism - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
